<?xml version="1.0" encoding="UTF-8"?>
<p>The development and expanding use of INSTIs in ARV-na√Øve and ARV-experienced patients make it increasingly important to survey INSTI resistance. Moreover, this is particularly important for patients with non-B viruses because of the lack of data about features of genetic variants and virological outcomes of treatment in these patients.</p>
